Abide’s platform exploits the power of chemoproteomics to mine the serine hydrolase superfamily for novel drug targets. Our platform includes a proprietary chemical library that is designed to interact with serine hydrolases, and cutting-edge chemoproteomics techniques that rapidly read out target engagement and off-target selectivity. Our strategy is to harness the therapeutic potential of serine hydrolases to yield drugs for treatment of a broad range of diseases in areas of unmet medical need.